Gene expression predicts differential capecitabine metabolism, impacting on both pharmacokinetics and antitumour activity

European Journal of Cancer

Volumn 44, Issue 2, 2008, Pages 310-317

  Guichard, Sylvie M ^a   Macpherson, Janet S ^a   Mayer, Iain ^a   Reid, Eilidh ^a   Muir, Morwenna ^a   Dodds, Michael ^a   Alexander, Susan ^a   Jodrell, Duncan I ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Capecitabine; Colorectal cancer; Gene expression; Metabolism; Pharmacokinetics

Indexed keywords

5' DEOXY 5 FLUOROCYTIDINE; CAPECITABINE; DOXIFLURIDINE; DRUG METABOLIZING ENZYME; FLUOROURACIL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; COLON CANCER; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG MONITORING; DRUG TUMOR LEVEL; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IC 50; LIVER CELL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANALYSIS OF VARIANCE; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; COLONIC NEOPLASMS; DEOXYCYTIDINE; FLUOROURACIL; GENE EXPRESSION; HEPATOCYTES; LIVER; MICE; MICE, INBRED C57BL; MICE, NUDE; NEOPLASM TRANSPLANTATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 38349025690     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2007.10.023     Document Type: Article

References (29)

1. Hoff P.M., Ansari R., Batist G., Cox J., Kocha W., Kuperminc M., et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19 8 (2001) 2282-2292
2. Scheithauer W., McKendrick J., Begbie S., Borner M., Burns W.I., Burris H.A., et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol 14 12 (2003) 1735-1743
3. Twelves C., Wong A., Nowacki M.P., Abt M., Burris III H., Carrato A., et al. Capecitabine as adjuvant treatment for stage III colon cancer. New Engl J Med 352 26 (2005) 2696-2704
4. Quinney S.K., Sanghani S.P., Davis W.I., Hurley T.D., Sun Z., Murry D.J., et al. Hydrolysis of capecitabine to 5′-deoxy-5-fluorocytidine by human carboxylesterases and inhibition by loperamide. J Pharmacol Exp Ther 313 3 (2005) 1011-1016 [Epub 2005 Feb 1]
5. Reigner B., Blesch K., and Weidekamm E. Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 40 2 (2001) 85-104
6. Wagstaff A.J., Ibbotson T., and Goa K.L. Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer. Drugs 63 2 (2003) 217-236
7. Tsukamoto Y., Kato Y., Ura M., Horii I., Ishitsuka H., Kusuhara H., et al. A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: the mechanism for tumor-selective accumulation of 5-FU. Pharm Res 18 8 (2001) 1190-1202
8. Gieschke R., Burger H.U., Reigner B., Blesch K.S., and Steimer J.L. Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients. Br J Clin Pharmacol 55 3 (2003) 252-263
9. Gieschke R., Reigner B., Blesch K.S., and Steimer J.L. Population pharmacokinetic analysis of the major metabolites of capecitabine. J Pharmacokinet Pharmacodyn 29 1 (2002) 25-47
10. Schuller J., Cassidy J., Dumont E., Roos B., Durston S., Banken L., et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 45 4 (2000) 291-297
11. Morita T., Matsuzaki A., Kurokawa S., and Tokue A. Forced expression of cytidine deaminase confers sensitivity to capecitabine. Oncology 65 3 (2003) 267-274
12. Ishikawa T., Utoh M., Sawada N., Nishida M., Fukase Y., Sekiguchi F., et al. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 55 7 (1998) 1091-1097
13. Miwa M., Ura M., Nishida M., Sawada N., Ishikawa T., Mori K., et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34 8 (1998) 1274-1281
14. Ninomiya I., Terada I., Yoshizumi T., Takino T., Nagai N., Morita A., et al. Anti-metastatic effect of capecitabine on human colon cancer xenografts in nude mouse rectum. Int J Cancer 112 1 (2004) 135-142
15. de Bruin M., van Capel T., Van der Born K., Kruyt F.A., Fukushima M., Hoekman K., et al. Role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity. Brit J Cancer 88 6 (2003) 957-964
16. Adlard J.W., Richman S.D., Seymour M.T., and Quirke P. Prediction of the response of colorectal cancer to systemic therapy. Lancet Oncol 3 2 (2002) 75-82
17. Macpherson J., Jodrell D., and Guichard S. Validation of real-time reverse-transcription-polymerase chain reaction for quantification of capecitabine-metabolising enzymes. Anal Biochem 350 1 (2006) 71-80
18. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82 13 (1990) 1107-1112
19. Workman P., Twentyman P., Balkwill F., Balmain A., Chaplin D., Double J., et al. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia. 2nd ed. Brit J Cancer 77 (1998) 1-10
20. Guichard S., Mayer I., and Jodrell D. Simultaneous determination of capecitabine and its metabolites by HPLC and mass spectrometry for preclinical and clinical studies. J Chromatogr B 826 1-2 (2005) 232-237
21. Tsukamoto Y., Kato Y., Ura M., Horii I., Ishikawa T., Ishitsuka H., et al. Investigation of 5-FU disposition after oral administration of capecitabine, a triple-prodrug of 5-FU, using a physiologically based pharmacokinetic model in a human cancer xenograft model: comparison of the simulated 5-FU exposures in the tumour tissue between human and xenograft model. Biopharm Drug Dispos 22 1 (2001) 1-14
22. Eliason J.F., and Megyeri A. Potential for predicting toxicity and response of fluoropyrimidines in patients. Curr Drug Targets 5 4 (2004) 383-388
23. el Kouni M.H., el Kouni M.M., and Naguib F.N. Differences in activities and substrate specificity of human and murine pyrimidine nucleoside phosphorylases: implications for chemotherapy with 5-fluoropyrimidines. Cancer Res 53 16 (1993) 3687-3693
24. Cao D., Leffert J.J., McCabe J., Kim B., and Pizzorno G. Abnormalities in uridine homeostatic regulation and pyrimidine nucleotide metabolism as a consequence of the deletion of the uridine phosphorylase gene. J Biol Chem 280 22 (2005) 21169-21175 [Epub 2005 Mar 16]
25. Peters G.J., Laurensse E., Leyva A., Lankelma J., and Pinedo H.M. Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5′-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes. Cancer Res 46 1 (1986) 20-28
26. Ishikawa T., Sekiguchi F., Fukase Y., Sawada N., and Ishitsuka H. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 58 4 (1998) 685-690
27. Mader R.M., Schrolnberger C., Rizovski B., Brunner M., Wenzel C., Locker G., et al. Penetration of capecitabine and its metabolites into malignant and healthy tissues of patients with advanced breast cancer. Br J Cancer 88 5 (2003) 782-787
28. Kirch H.C., Schroder J., Hoppe H., Esche H., Seeber S., and Schutte J. Recombinant gene products of two natural variants of the human cytidine deaminase gene confer different deamination rates of cytarabine in vitro. Exp Hematol 26 5 (1998) 421-425
29. Klomp D., van Laarhoven H., Scheenen T., Kamm Y., and Heerschap A. Quantitative (19)F MR spectroscopy at 3 T to detect heterogeneous capecitabine metabolism in human liver. NMR Biomed 20 5 (2007) 485-492